Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.53 |
| ▸ | MYC | P01106 | 1/20 | 0.49 |
| ▸ | LDHA | P00338 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | KDM5A | P29375 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.46 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.45 |
| ▸ | EIF4E | P06730 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | GABRP | O00591 | 1/20 | 0.41 |
| ▸ | GABRD | O14764 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7111091 | 0.87 | GPBAR1 (0.52) | GPBAR1MYCPOLQ | |
| SCHEMBL5781412 | 0.84 | ALDH1A1 (0.47) | EIF4EKDM4EALDH1A1TSHRHPGD | |
| SCHEMBL905344 | 0.84 | GPBAR1 (0.50) | GPBAR1FTONPC1GAARAB9A | |
| SCHEMBL29186263 | 0.83 | NAPRT (0.45) | LDHAKDM4EALDH1A1TSHRHPGD | |
| SCHEMBL5783181 | 0.82 | GPBAR1 (0.53) | GPBAR1LDHAKDM4EUSP2ALDH1A1 | |
| SCHEMBL3872238 | 0.82 | EIF4E (0.47) | MYCLDHAEIF4EKDM4EALDH1A1 | |
| SCHEMBL31297029 | 0.81 | CLCN2 (0.47) | EIF4EKDM4EALDH1A1HPGDDHODH | |
| SCHEMBL7110905 | 0.81 | GPBAR1 (0.53) | GPBAR1ALDH1A1TSHRHPGDNPC1 | |
| SCHEMBL7110261 | 0.81 | GPBAR1 (0.47) | GPBAR1ALDH1A1TSHRNPC1RAB9A | |
| SCHEMBL27541520 | 0.81 | DDT (0.51) | LDHAALDH1A1HPGDDHODHGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112979543-B | Substituted 4-phenylpyridines for the treatment of NK-1 receptor related diseases | 赫尔森保健股份公司 | 2024-09-24 | — | — | CN | disclosed |
| US-12071421-B2 | Process for the synthesis of substituted chloromethyl dialkylphosphates | HELSINN HEALTHCARE SA (CH) | 2024-08-27 | — | — | US | disclosed |
| CN-111662330-B | Substituted 4-phenylpyridines for the treatment of NK-1 receptor related diseases | 赫尔森保健股份公司 | 2023-05-12 | — | — | CN | disclosed |
| US-20220401463-A1 | SUBSTITUTED 4-PHENYL-PYRIDINES | HELSINN HEALTHCARE SA (CH) | 2022-12-22 | — | — | US | disclosed |
| US-11312698-B2 | Fosnetupitant chloride hydrochloride having improved stability | HELSINN HEALTHCARE SA (CH) | 2022-04-26 | — | — | US | disclosed |
| CN-112979543-A | Substituted 4-phenylpyridines for the treatment of NK-1 receptor related diseases | 赫尔森保健股份公司 | 2021-06-18 | — | — | CN | disclosed |
| CN-112961104-A | Substituted 4-phenylpyridines for the treatment of NK-1 receptor related diseases | 赫尔森保健股份公司 | 2021-06-15 | — | — | CN | disclosed |
| US-20200399240-A1 | SUBSTITUTED 4-PHENYL-PYRIDINES | HELSINN HEALTHCARE SA (CH) | 2020-12-24 | — | — | US | disclosed |
| CN-111662330-A | Substituted 4-phenylpyridines for the treatment of NK-1 receptor related diseases | 赫尔森保健股份公司 | 2020-09-15 | — | — | CN | disclosed |
| US-10717721-B2 | Substituted piperaziniums for the treatment of emesis | HELSINN HEALTHCARE SA (CH) | 2020-07-21 | — | — | US | disclosed |
| EP-2785706-A1 | SUBSTITUTED 4 - PHENYL - PYRIDINES FOR THE TREATMENT OF NK-1 RECEPTOR RELATED DISEASES | Helsinn Healthcare SA (CH) | 2014-10-08 | — | — | EP | disclosed |
| US-20130231315-A1 | MODIFIED 4-PHENYL-PYRIDINE DERIVATIVES | HELSINN HEALTHCARE SA (CH) | 2013-09-05 | — | — | US | disclosed |
| WO-2013082102-A1 | SUBSTITUTED 4 - PHENYL - PYRIDINES FOR THE TREATMENT OF NK-1 RECEPTOR RELATED DISEASES | HELSINN HEALTHCARE SA (CH) | 2013-06-06 | — | — | WO | disclosed |
| US-8426450-B1 | Substituted 4-phenyl pyridines having anti-emetic effect | HELSINN HEALTHCARE SA (CH) | 2013-04-23 | — | — | US | disclosed |
| EP-1103546-B1 | Process for preparation of pyridine derivatives | HOFFMANN LA ROCHE (CH) | 2003-10-22 | — | — | EP | disclosed |
| US-6479483-B2 | 3,4,6-SUBSTITUTED PYRIDINE DERIVATIVES USEFUL FOR TREATING DEPRESSION AND PAIN, RESULTING FROM INFLAMMATORY CONDITIONS, SUCH AS MIGRAINE, RHEUMATOID ARTHRITIS, ASTHMA AND INFLAMATORY BOWEL DISEASE; NK1 RECEPTOR ANTAGONIST | HOFFMANN-LA ROCHE INC. | 2002-11-12 | — | — | US | disclosed |
| US-20020091265-A1 | 4-phenyl-pyridine derivatives | BOS MICHAEL (CA) | 2002-07-11 | — | — | US | disclosed |
| US-6303790-B1 | REACTING SUBSTITUTED NICOTINAMIDE WITH GRIGNARD REAGENT, OXIDIZING PRODUCT, REACTING WITH HALO-SUBSTITUTED AROMATIC COMPOUND | HOFFMAN-LA ROCHE INC. | 2001-10-16 | — | — | US | disclosed |
| US-6297375-B1 | 4-phenyl-pyridine derivatives | HOFFMANN-LA ROCHE INC. | 2001-10-02 | — | — | US | disclosed |
| EP-1103546-A1 | Process for preparation of pyridine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312698-B2 | Fosnetupitant chloride hydrochloride having improved stability | FOS, FOSB, CLCN2 | GPBAR1 1531/4885MYC 251/4885LDHA 2443/4885 |
| US-20200399240-A1 | SUBSTITUTED 4-PHENYL-PYRIDINES | BDKRB2, BDKRB1, TACR1 | GPBAR1 40/4885MYC 2502/4885LDHA 2723/4885 |
| US-20220401463-A1 | SUBSTITUTED 4-PHENYL-PYRIDINES | BDKRB2, BDKRB1, TACR1 | GPBAR1 40/4885MYC 2502/4885LDHA 2723/4885 |
| US-20130231315-A1 | MODIFIED 4-PHENYL-PYRIDINE DERIVATIVES | BDKRB2, BDKRB1, TACR1 | GPBAR1 47/4885MYC 2782/4885LDHA 2957/4885 |
| US-20020091265-A1 | 4-phenyl-pyridine derivatives | CBR1, CBR3, HCCS | GPBAR1 327/4885MYC 3774/4885LDHA 3437/4885 |
| US-12071421-B2 | Process for the synthesis of substituted chloromethyl dialkylphosphates | BDKRB1, BDKRB2, TK1 | GPBAR1 349/4885MYC 1113/4885LDHA 3779/4885 |
| US-10717721-B2 | Substituted piperaziniums for the treatment of emesis | VIPR2, VIPR1, GRPR | GPBAR1 85/4885MYC 3980/4885LDHA 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.